EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Research progress on the triglyceride–glucose index in different development stages and outcomes of ischemic stroke: A narrative review

Ping Li, Jiang Chang, Xinyue Zhang, Dong Han

Brain Circulation · 2026-05-25

DOI: 10.4103/bc.bc_200_25 ↗
AbstractBibliografische Angaben

Abstract

Abstract: The triglyceride–glucose (TyG) index, recognized as a novel surrogate marker for insulin resistance (IR), has been established by multiple studies to be significantly associated with ischemic stroke. Current evidence indicates that the TyG index is closely correlated with the risk of ischemic stroke onset, disease progression (clinical deterioration), clinical prognosis, recurrence, and mortality. This suggests its potential utility as a biomarker reflecting different stages of ischemic stroke (e.g., acute, recovery, and chronic phases) and prognostic outcomes (e.g., functional recovery, recurrence, and mortality). However, there remains a lack of systematic reviews comprehensively examining the correlation between the TyG index and the various stages of ischemic stroke and their prognostic outcomes, along with an exploration of the underlying mechanisms. This review aims to systematically elucidate the background and evidence establishing the TyG index as a surrogate marker for IR, explore the potential mechanisms by which it contributes to the pathogenesis and progression of ischemic stroke from the core pathophysiological perspective of IR, while concurrently critically evaluating the existing research evidence on the association between the TyG index and the different stages of ischemic stroke as well as prognostic outcomes, and highlighting current research limitations. By synthesizing current knowledge, this review expects to provide a theoretical foundation for utilizing the TyG index to identify high-risk populations for ischemic stroke at an early stage and predict the risk of adverse prognostic outcomes (including disease progression and mortality), thereby exploring its potential clinical applications and early-warning value.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →